Cell Proliferation Assessed by Ki-67 Immunoreactivity on Formalin Fixed Tissues is a Predictive Factor for Survival in Prostate Cancer
- 1 January 1997
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 157 (1), 219-222
- https://doi.org/10.1016/s0022-5347(01)65330-8
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Determination of Ki‐67 defined growth fraction by monoclonal antibody MIB‐i in formalin‐fixed, paraffin‐embedded prostatic cancer tissuesThe Prostate, 1995
- Mitotic activity and prognosis in prostatic adenocarcinomaThe Prostate, 1995
- Changes in prostate cancer incidence and treatment in USAThe Lancet, 1994
- New antiserum against Ki-67 antigen suitable for double immunostaining of paraffin wax sections.Journal of Clinical Pathology, 1993
- Evaluation of Ki‐67 Monoclonal Antibody as Prognostic Indicator for Prostatic CarcinomaBJU International, 1993
- Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prostatic carcinomaThe Journal of Pathology, 1992
- Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parametersThe Prostate, 1992
- Pathological and clinical associations of Ki-67 defined growth fractions in human prostatic carcinomaThe Prostate, 1992
- A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fractionThe Journal of Pathology, 1991
- The clinical assessment of proliferation and growth in human tumours: Evaluation of methods and applications as prognostic variablesThe Journal of Pathology, 1990